Novo Nordisk Turns Rival Hims & Hers Into Sales Partner
Novo Nordisk has struck a significant and unexpected partnership with telehealth platform Hims & Hers, fundamentally altering their relationship from legal adversaries to business allies. Under the agreement, Hims & Hers will sell Novo Nordisk's official, FDA-approved blockbuster weight-loss drugs Wegovy and Ozempic directly through its platform. This deal resolves a contentious legal feud where Novo Nordisk had been suing Hims for patent infringement over the sale of compounded, or "copycat," versions of its treatments.
The market reaction was immediate and pronounced. Shares of Hims & Hers skyrocketed 40% as the deal removed a massive legal and operational risk from its business model. Novo Nordisk's stock experienced a volatile session on March 26, initially falling 3.2% before reversing to close up over 2% as investors digested the strategic benefits of the new sales channel and the resolution of the legal battle.
New Catalysts Combat 28% Stock Decline
The Hims partnership provides a critical new distribution channel for Novo Nordisk as it intensifies its fight against rival Eli Lilly for dominance in the GLP-1 drug market. The move serves as a strategic counter-offensive for the company, whose stock had fallen 28% this year on investor fears that it was losing ground. With the stock trading at a price-to-earnings ratio of just over 10, the market had been pricing in significant competitive risk.
This partnership follows another recent strategic victory for Novo Nordisk: the FDA's approval of Wegovy HD. The higher-dose version demonstrated an average weight loss of 20.7% in clinical trials, significantly narrowing the efficacy gap with Eli Lilly's Zepbound, which averages 22.5% weight loss. Previously, the standard Wegovy dose averaged around 15% loss. Together, the enhanced product and new sales channel position Novo Nordisk to better defend its market share and challenge bearish sentiment.
